Price (delayed)
$5.86
Market cap
$381.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.3
Enterprise value
$341.83M
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its ...
Highlights
The EPS has surged by 67% year-on-year and by 63% since the previous quarter
CorMedix's net income has soared by 61% YoY and by 61% from the previous quarter
The quick ratio has shrunk by 54% YoY and by 11% QoQ
Key stats
What are the main financial stats of CRMD
MarketValuationsEarnings
Shares outstanding
65.18M
Market cap
$381.97M
Enterprise value
$341.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.2
Price to sales (P/S)
7.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.86
Revenue
$43.47M
Gross profit
$40.28M
Operating income
-$22.36M
Net income
-$17.93M
EBIT
-$19.29M
EBITDA
-$18.98M
Free cash flow
-$50.73M
Per shareBalance sheetLiquidity
EPS
-$0.3
EPS diluted
-$0.3
Free cash flow per share
-$0.86
Book value per share
$1.4
Revenue per share
$0.74
TBVPS
$1.99
Total assets
$118.85M
Total liabilities
$34.19M
Debt
$517,013
Equity
$84.66M
Working capital
$80.74M
Debt to equity
0.01
Current ratio
3.39
Quick ratio
3.05
Net debt/EBITDA
2.11
MarginsEfficiencyDividend
EBITDA margin
-43.7%
Gross margin
92.7%
Net margin
-41.2%
Operating margin
-51.4%
Return on assets
-22.3%
Return on equity
-29%
Return on invested capital
-74.1%
Return on capital employed
-22.7%
Return on sales
-44.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRMD stock price
How has the CorMedix stock price performed over time
Intraday
-3.93%
1 week
-13.06%
1 month
-40.51%
1 year
31.39%
YTD
-27.65%
QTD
-4.87%
Financial performance
How have CorMedix's revenue and profit performed over time
Revenue
$43.47M
Gross profit
$40.28M
Operating income
-$22.36M
Net income
-$17.93M
Gross margin
92.7%
Net margin
-41.2%
CRMD financials
The company's net margin has surged by 89% QoQ
CorMedix's operating margin has surged by 88% QoQ
CorMedix's net income has soared by 61% YoY and by 61% from the previous quarter
The company's operating income has surged by 56% QoQ and by 54% YoY
Growth
What is CorMedix's growth rate over time
CRMD growth chart
Valuation
What is CorMedix stock price valuation
P/E
N/A
P/B
4.2
P/S
7.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.86
Price to earnings (P/E)
The EPS has surged by 67% year-on-year and by 63% since the previous quarter
Price to book (P/B)
CorMedix's equity has increased by 44% QoQ and by 21% YoY
The P/B is 26% below the last 4 quarters average of 5.7
Price to sales (P/S)
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 1738.9
Efficiency
How efficient is CorMedix business performance
The return on sales has surged by 89% since the previous quarter
The ROA has soared by 66% from the previous quarter and by 65% YoY
The company's return on invested capital has surged by 65% QoQ and by 52% YoY
CorMedix's ROE has soared by 63% from the previous quarter and by 60% YoY
Dividends
What is CRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRMD.
Financial health
How did CorMedix financials performed over time
Assets vs liabilities
CorMedix's total liabilities has surged by 187% YoY and by 81% QoQ
The quick ratio has shrunk by 54% YoY and by 11% QoQ
Debt vs equity
The company's debt is 99% lower than its equity
CorMedix's equity has increased by 44% QoQ and by 21% YoY
The company's debt fell by 23% YoY and by 7% QoQ
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.